ArticleFrontiers in medicine2026
Body mass index adjusted aspirin dosing does not overcome pharmacokinetic and pharmacodynamic disadvantages in obese pregnant women at risk for preeclampsia: a prospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess if aspirin dosed based on a patient's body mass index (BMI) would yield similar pharmacokinetics and pharmacodynamics for obese compared to non-obese patients who are taking aspirin to prevent preeclampsia. Methods: This prospective cohort study included 35 pregnant women at high-risk of developing preeclampsia from Haseki Training and Research Hospital, Istanbul, Türkiye. Participants were prospectively stratified (non-randomized) into two groups based on baseline BMI: Group 1 ( Results: Although the obese group was administered 50% more aspirin, they had 17% lower serum salicylate levels at follow-up (mean ± SD 2.08 ± 0.23 vs. 2.52 ± 0.32 μg/mL, Conclusion: In this non-randomized cohort, a 150 mg aspirin dose did not appear to overcome the pharmacokinetic and pharmacodynamic disadvantages associated with obesity in pregnant women. Other dosing approaches, such as weight-based dosing or twice-daily administration, should be evaluated to optimize preeclampsia prophylaxis in obese pregnancies. These findings require confirmation in larger randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.